

**From:** s22  
**To:** s47F s  
**Cc:** s47F  
**Subject:** RE: 5.06 Fremanezumab: additional analysis [SEC=OFFICIAL]  
**Date:** Wednesday, 6 November 2019 10:07:42 AM  
**Attachments:** [image002.png](#)  
[image003.png](#)  
[image004.png](#)  
[image005.png](#)  
[image006.png](#)  
[image007.png](#)

---

Thanks s47F Good to know the revised calcs match mine!  
s47E(d), s47, s47C, s47G, s38 (and different mark ups apply), the calculation should be:  
s47E(d), s47, s47C, s47G, s38

s47E(d), s47, s47C, s47G, s38

But will need to check that one with my pricing colleagues!

Cheers,  
s22

---

**From:** s47F  
**Sent:** Wednesday, 6 November 2019 9:51 AM  
**To:** s22  
**Cc:** s47F  
**Subject:** RE: 5.06 Fremanezumab: additional analysis [SEC=OFFICIAL]  
H s22 ,

It looks like there is an error in the application of the s47E(d), s47, s47C, s47G,  
s38

**Fremanezumab 12-weekly weighted price proposed in the submission:**

The proposed DPMQ in the submission for fremanezumab 12-weekly is s47E(d), s47, s47C,  
s47G, s38

s38, s47C

**Fremanezumab 12-weekly weighted price based on the** s47E(d), s47, s47C,  
s47G, s38

s47E(d), s47, s47C,  
s47G, s38

Feel free to contact me if any further clarification is required.

Kind regards,

s47F

s47F

T: s47F

E: s47F

s47F

DOCUMENT RELEASED UNDER  
THE FREEDOM OF INFORMATION ACT 1982 (CTH)  
BY THE DEPARTMENT OF HEALTH



---

**From:** s22

**Sent:** Tuesday, 5 November 2019 3:07 PM

**To:** s47F

**Cc:** s47F

s22

**Subject:** RE: 5.06 Fremanezumab: additional analysis [SEC=OFFICIAL]

Hi s47F

s47E(d), s47, s47C, s47G, s38

s47E(d), s47, s47C, s47G, s38

Can you please double check the calc?

And can I please check how you calculated the s47E(d), s47, s47C, s47G, s38

Many thanks!

Kind regards,

s22

---

**From:** s22 >

**Sent:** Tuesday, 22 October 2019 1:22 PM

**To:** s47F

s22

**Cc:** s22

s22

s47F

**Subject:** RE: 5.06 Fremanezumab: additional analysis [SEC=OFFICIAL]

Thank you so much, s22

And thanks for your clear explanation below.

Kind regards,

s22

---

**From:** s47F

**Sent:** Tuesday, 22 October 2019 12:56 PM

**To:** s22

**Cc:** s22

s22

>; s47F

**Subject:** RE: 5.06 Fremanezumab: additional analysis [SEC=OFFICIAL]

Hi s22

Please find additional sensitivity analyses attached.

s47E(d), s47, s47C, s47G, s38

DOCUMENT RELEASED UNDER  
THE FREEDOM OF INFORMATION ACT 1982 (CTH)  
BY THE DEPARTMENT OF HEALTH

s47F

s47F

T: s47F  
E: s47F

s47F



---

**From:** s47F

**Sent:** Tuesday, 22 October 2019 10:51 AM

**To:** s22

**Cc:** s22

; s47F

**Subject:** RE: 5.06 Fremanezumab: additional analysis [SEC=OFFICIAL]

Hi s22

We are working on this and will send a response when we can.

Cheers,

s47F

s47F

T: s47F  
E: s47F

s47F

s47F



---

**From:** s22

**Sent:** Monday, 21 October 2019 8:59 PM

**To:** s47F

Cc: s22

**Subject:** 5.06 Fremanezumab: additional analysis [SEC=OFFICIAL]

**Importance:** High

Hi s47F

As mentioned at the ESC meeting, s47E(d), s47, s47C, s47G, s38

I also note your response to this analysis:

s47E(d), s47, s47C, s47G, s38

Can you let me know whether the analysis can be done? If possible could you please let me know by mid-morning Tuesday (sorry – we're trying to finalise the ESC ADV!).

Many thanks, s22 !

Kind regards,

s22

---

PBAC Secretariat

Office of Health Technology Assessment | Technology Assessment & Access Division

Australian Government Department of Health

T: s22

E: Is22

---

"Important: This transmission is intended only for the use of the addressee and may contain confidential or legally privileged information. If you are not the intended recipient, you are notified that any use or dissemination of this communication is strictly prohibited. If you receive this transmission in error please notify the author immediately and delete all copies of this transmission."

---

"Important: This transmission is intended only for the use of the addressee and may contain confidential or legally privileged information. If you are not the intended recipient, you are notified that any use or dissemination of this communication is strictly prohibited. If you receive this transmission in error please notify the author immediately and delete all copies of this transmission."